RxDoctor Payments Data

Suzanna Fuller

Family · Nacogdoches, TXNPI 1326504382

Payments from drug & device makers

$1,658in general payments, 2019–2025

Across 95 payments — averaging $17.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$366
  • Lilly USA, LLC$267
  • AstraZeneca$229
  • Exact Sciences$120
  • Dexcom, Inc.$112
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$96
  • plus $469 from 12 others

What the payments were for

  • Food & beverage$1,61397%
  • Education$453%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,658 in reported general payments places this provider in the 75th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$42,120
Medicare patients
96
Services billed
648

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide227$274,057
OzempicSemaglutide33$49,866
EliquisApixaban43$41,242
Breztri AerosphereBudesonide/Glycopyr/Formoterol35$26,290
TrulicityDulaglutide14$19,970
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$17,049
Tresiba Flextouch U-200Insulin Degludec27$14,791
XareltoRivaroxaban15$12,553
MyrbetriqMirabegron17$11,702
JardianceEmpagliflozin15$8,865
Gabapentin92$1,938
Levothyroxine Sodium128$1,396
Tramadol Hcl137$1,335
Scopolamine14$1,306
Atorvastatin Calcium126$1,078

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$267$294,028241 claims
Novo NordiskOzempic$366$49,86633 claims
PfizerEliquis$31$41,24243 claims
AstraZenecaBreztri Aerosphere$229$26,29035 claims
GSKTrelegy Ellipta$74$17,04925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 15,456 family providers in Texas.

Other family in Nacogdoches

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →